MedTrace Logo

Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis

NCT05067348 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-05-01

No results posted yet for this study

Summary

Randomized, double-blind, placebo-controlled, parallel-group study with optional open-label extension.

Conditions

  • Myasthenia Gravis, Generalized

Interventions

DRUG

Tocilizumab Injectable Product

Participants will receive IV tocilizumab

Sponsors & Collaborators

  • Tang-Du Hospital

    lead OTHER

Principal Investigators

  • Ting Chang, MD,PHD · The Second Affiliated Hospital of Air Force Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-21
Primary Completion
2025-12-31
Completion
2026-03-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05067348 on ClinicalTrials.gov